1,581 reports of this reaction
2.1% of all TORSEMIDE reports
#8 most reported adverse reaction
GENERAL PHYSICAL HEALTH DETERIORATION is the #8 most commonly reported adverse reaction for TORSEMIDE, manufactured by Sarfez Pharmaceuticals Inc. There are 1,581 FDA adverse event reports linking TORSEMIDE to GENERAL PHYSICAL HEALTH DETERIORATION. This represents approximately 2.1% of all 74,224 adverse event reports for this drug.
TORSEMIDE has an overall safety score of 85 out of 100. Patients taking TORSEMIDE who experience general physical health deterioration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GENERAL PHYSICAL HEALTH DETERIORATION is a less commonly reported adverse event for TORSEMIDE, but still significant enough to appear in the safety profile.
In addition to general physical health deterioration, the following adverse reactions have been reported for TORSEMIDE:
The following drugs have also been linked to general physical health deterioration in FDA adverse event reports:
GENERAL PHYSICAL HEALTH DETERIORATION has been reported as an adverse event in 1,581 FDA reports for TORSEMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GENERAL PHYSICAL HEALTH DETERIORATION accounts for approximately 2.1% of all adverse event reports for TORSEMIDE, making it a notable side effect.
If you experience general physical health deterioration while taking TORSEMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.